Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (Gb3) for reversal of multidrug resistance to cancer chemotherapy

Toxins

Volumn 2, Issue 10, 2010, Pages 2467-2477

  Behnam Motlagh, Parviz ^a   Tyler, Andreas ^a   Grankvist, Kjell ^a   Johansson, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Cancer; Gb3; Mdr1; Multi drug resistance; P gp; Verotoxin 1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GLOBOTRIAOSYLCERAMIDE MEMBRANE RECEPTOR 3; GLYCOPROTEIN P; GLYCOSPHINGOLIPID; HOLOTOXIN; MEMBRANE RECEPTOR; SHIGA TOXIN; UNCLASSIFIED DRUG; VEROTOXIN 1;

APOPTOSIS; ASTROCYTOMA; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG TARGETING; GENE OVEREXPRESSION; IMMUNOMODULATION; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MDR1 ONCOGENE; MENINGIOMA; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE; PLEURA MESOTHELIOMA; REVIEW; TUMOR CELL;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOSPHINGOLIPIDS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; SHIGA TOXIN 1;

EID: 79952096407     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins2102467     Document Type: Review

References (80)

1. Cohen, A.; Hannigan, G.E.; Williams, B.R.; Lingwood, C.A. Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J. Biol. Chem. 1987, 262, 17088-17091.
2. Lingwood, C.A.; Law, H.; Richardson, S.; Petric, M.; Brunton, J.L.; De Grandis, S.; Karmali, M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 1987, 262, 8834-8839.
3. Jacewicz, M.; Feldman, H.A.; Donohue-Rolfe, A.; Balasubramanian, K.A.; Keusch, G.T. Pathogenesis of Shigella diarrhea. XIV. Analysis of Shiga toxin receptors on cloned HeLa cells. J. Infect. Dis. 1989, 159, 881-889.
4. Lindberg, A.A.; Brown, J.E.; Strömberg, N.; Westling-Ryd, M.; Schultz, J.E.; Karlsson, K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 1987, 262, 1779-1785.
5. Waddell, T.; Cohen, A.; Lingwood, C.A. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc. Natl. Acad. Sci. USA 1990, 87, 7898-7901.
6. Endo, Y.; Tsurugi, K.; Yutsudo, T.; Takeda, Y.; Ogasawara, T.; Igarashi, K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171, 45-50.
7. Gariepy, J. The use of Shiga-like toxin 1 in cancer therapy. Crit. Rev. Oncol. Hematol. 2001, 39, 99-106.
8. O'Brien, A.D.; Tesh, V.L.; Donohue-Rolfe, A.; Jackson, M.P.; Olsnes, S.; Sandvig, K.; Lindberg, A.A.; Keusch, G.T. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 1992, 180, 65-94.
9. Olsnes, S.; Sandvig, K. How protein toxins enter and kill cells. Canc. Treat. Res. 1988, 37, 39-73.
10. Raa, H.; Grimmer, S.; Schwudke, D.; Bergan, J.; Walchli, S.; Skotland, T.; Shevchenko, A.; Sandvig, K. Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin. Traffic 2009, 10, 868-882.
11. Sandvig, K.; Grimmer, S.; Lauvrak, S.U.; Torgersen, M.L.; Skretting, G.; van Deurs, B.; Iversen, T.G. Pathways followed by ricin and Shiga toxin into cells. Histochem. Cell Biol. 2002, 117, 131-141.
12. Saxena, S.K.; O'Brien, A.D.; Ackerman, E.J. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J. Biol. Chem. 1989, 264, 596-601.
13. Kojio, S.; Zhang, H.; Ohmura, M.; Gondaira, F.; Kobayashi, N.; Yamamoto, T. Caspase-3 activation and apoptosis induction coupled with the retrograde transport of Shiga toxin: Inhibition by brefeldin A. FEMS Immunol. Med. Microbiol. 2000, 29, 275-281.
14. Johannes, L.; Römer, W. Shiga toxins-From cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8, 105-116.
15. Johansson, D.; Andersson, C.; Moharer, J.; Johansson, A.; Behnam-Motlagh, P. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells. Br. J. Canc. 2010, 19, 383-391.
16. Derijard, B.; Raingeaud, J.; Barrett, T.; Wu, I.H.; Han, J.; Ulevitch, R.J.; Davis, R.J. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267, 682-685.
17. Han, J.; Lee, J.D.; Jiang, Y.; Li, Z.; Feng, L.; Ulevitch, R.J. Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. 1996, 271, 2886-2891.
18. Kim, B.J.; Ryu, SW.; Song, B.J. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J. Biol. Chem. 2006, 281, 21256-21265.
19. Walchli, S.; Skanland, S.S.; Gregers, T.F.; Lauvrak, S.U.; Torgersen, M.L.; Ying, M.; Kuroda, S.; Maturana, A.; Sandvig, K. The Mitogen-activated protein kinase p38 links Shiga Toxin-dependent signaling and trafficking. Mol. Biol. Cell 2008, 19, 95-104.
20. Lee, S.Y.; Cherla, R.P.; Tesh, V.L. Simultaneous induction of apoptotic and survival signaling pathways in macrophage-like THP-1 cells by Shiga toxin 1. Infect. Immun. 2007, 75, 1291-1302.
21. Johansson, D.; Johansson, A.; Grankvist, K.; Andersson, U.; Henriksson, R.; Bergström, P.; Brännström, T.; Behnam-Motlagh, P. Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines. Canc. Biol. Ther. 2006, 5, 1211-1217.
22. Johansson, D.; Kosovac, E.; Moharer, J.; Ljuslinder, I.; Brännström, T.; Johansson, A.; Behnam-Motlagh, P. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer 2009, 9, 67.
23. Jones, N.L.; Islur, A.; Haq, R.; Mascarenhas, M.; Karmali, M.A.; Perdue, M.H.; Zanke, B.W.; Sherman, P.M. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278, G811-G819.
24. Suzuki, A.; Doi, H.; Matsuzawa, F.; Aikawa, S.; Takiguchi, K.; Kawano, H.; Hayashida, M.; Ohno, S. Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: Possible association between Bcl-2 and tissue failure by E. coli O157:H7. Genes Dev. 2000, 14, 1734-1740.
25. Erwert, R.D; Eiting, K.T.; Tupper, J.C.; Winn, R.K.; Harlan, J.M.; Bannerman, D.D. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb. Pathog. 2003, 35, 87-93.
26. Janson, V.; Henriksson, R.; Grankvist, K. Acquisition of cisplatin-resistance in malignant mesothelioma cells reregulates pro-apoptotic BH3-only proteins. PhD Thesis, Umea University, Umea, Sweden, 2010, in preparation.
27. Janson, V.; Johansson, A.; Grankvist, K. Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cosplatin-resistance. Cell Death Dis. 2010, 1, e78.
28. Erdmann, M.; Wipfler, D.; Merling, A.; Cao, Y.; Claus, C.; Kniep, B.; Sadick, H.; Bergler, W.; Vlasak, R.; Schwartz-Albiez, R. Differential surface expression and possible function of 9-O- and 7-O-acetylated GD3 (CD60 b and c) during activation and apoptosis of human tonsillar B and T lymphocytes. Glycoconj. J. 2006, 23, 627-638.
29. Alessandri, G.; De Cristan, G.; Ziche, M.; Cappa, A.P.; Gullino, P.M. Growth and motility of microvascular endothelium are modulated by the relative concentration of gangliosides in the medium. J. Cell Physiol. 1992, 151, 23-28.
30. Lahiri, S.; Futerman, A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 2007, 64, 2270-2284.
31. Schnaar, R.L. Glycolipid-mediated cell-cell recognition in inflammation and nerve regeneration. Arch. Biochem. Biophys. 2004, 426, 163-172.
32. Liu, Y.Y.; Gupta, V.; Patwardhan, G.A.; Bhinge, K.; Zhao, Y.; Bao, J.; Mehendale, H.; Cabot, M.C.; Li, Y.T.; Jazwinski, S.M. Glucosylceramide synthase upregulate Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol. Cancer 2010, 9, 145.
33. Okuda, T.; Tokuda, N.; Numata, S.; Ito, M.; Ohta, M.; Kawamura, K.; Wiels, J.; Urano, T.; Tajima, O.; Furukawa, K.; Furukawa, K. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J. Biol. Chem. 2006, 281, 10230-10235.
34. Lingwood, C.A.; Binnington, B.; Manis, A.; Branch, D.R. Globotriaosyl ceramide receptor function-Where membrane structure and pathology intersect. FEBS Lett. 2010, 3, 1879-1886.
35. Chen, J.K.; Capdevila, J.; Harris, R.C. Overexpression of C-terminal Src kinase blocks 14, 15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. J. Biol. Chem. 2000, 275, 13789-13792.
36. Kazui, A.; Ono, M.; Handa, K.; Hakomori, S. Glycosylation affects translocation of integrin, Src,and caveolin into or out of GEM. Biochem. Biophys. Res. Commun. 2000, 273, 159-163.
37. Hakomori, S.; Zhang, Y. Glycosphingolipid antigens and cancer therapy. Chem. Biol. 1997, 4, 97-104.
38. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature 1997, 387, 569-572.
39. Lingwood, C.A. Aglycone modulation of glycolipid receptor function. Glycoconj. J. 1996, 13, 495-503.
40. Sandvig, K.; Garred, O.; van Helvoort, A.; van Meer, G.; van Deurs B. Importance of glycolipid synthesis for butyric acid-induced sensitization to Shiga toxin and intracellular sorting of toxin in A431 cells. Mol. Biol. Cell 1996, 7, 1391-1404.
41. Kovbasnjuk, O.; Edidin, M.; Donowitz, M. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J. Cell Sci. 2001, 114, 4025-4031.
42. Falguières, T.; Maak, M.; von Weyhern, C.; Sarr, M.; Sastre, X.; Poupon, M-F.; Robine, S.; Johannes, L.; Janssen, K-P. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol. Cancer Ther. 2008, 7, 2498-2508.
43. Smith, D.C.; Sillence, D.J.; Falguieres, T.; Jarvis, R.M.; Johannes, L.; Lord, J.M.; Platt, F.M.; Roberts, L.M. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol. Biol. Cell 2006, 17, 1375-1387.
44. Falguieres, T.; Mallard, F.; Baron, C.; Hanau, D.; Lingwood, C.; Goud, B.; Salamero, J.; Johannes, L. Targeting of Shiga toxin b-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell 2001, 12, 2453-2468.
45. Römer, W.; Berland, L.; Chambon, V.; Gaus, K.; Windschiegl, B.; Tenza, D.; Aly, M.R.; Fraisier, V.; Florent, J.C.; Perrais, D.; Lamaze, C.; Raposo, G.; Steinem, C.; Sens, P.; Bassereau, P.; Johannes, L. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007, 450, 670-675.
46. Khan, F.; Proulx, F.; Lingwood, C.A. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomerular restricted hemolytic uremic syndrome pathology. Kidney Int. 2009, 75,1135-1137.
47. Kang, E.; Rajpert-De Meyts, E.; Wiels J.; Skakkebæk, N.E. Expression of the glycolipid globotriaosylceramide (Gb3) in testicular carcinoma in situ. Virchows Arch. 1995, 426, 369-374.
48. LaCasse, E.C.; Bray, M.R.; Patterson, B.; Lim, W.M.; Perampalam, S.; Radvanyi, L.G.; Keating, A.; Stewart, A.K.; Buckstein, R.; Sandhu, J.S.; Miller, N.; Banerjee, D.; Singh, D.; Belch, A.R.; Pilarski, L.M.; Gariépy, J. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 1999, 94, 2901-2910.
49. Arab, S.; Russel, E.; Chapman, W.B.; Rosen, B.; Lingwood, C.A. Expression of the verotoxin receptor glycolipid, globotriaosylceramide, in ovarian hyperplasias. Oncol. Res. 1997, 9, 553-563.
50. Kovbasnjuk, O.; Mourtazina, R.; Baibakov, B.; Wang, T.; Elowsky, C.; Choti, M.A.; Kane, A.; Donowitz, M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc. Natl. Acad. Sci. USA. 2005, 102, 19087-19092.
51. De Rosa, M.F.; Ackerley, C.; Wang, B.; Ito, S.; Clarke, D.M.; Lingwood, C. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog. J. Biol. Chem. 2008, 22, 4501-4511.
52. Mattocks, M.; Bagovich, M.; De Rosa, M.; Bond, S.; Binnington, B.; Rasaiah, V.I.; Medin, J.; Lingwood, C. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model. FEBS J. 2006, 2739, 2064-2075.
53. Sikic, B.I. Modulation of multidrug resistance: A paradigm for translational clinical research. Oncology 1999, 13, 183-187.
54. Gottesman, M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53, 615-627.
55. Kourousis, C.; Kakolyris, S.; Androulakis, N.; Heras, P.; Vlachonicolis, J.; Vamvakas, L.; Vlata, M.; Hatzidaki, D.; Samonis, G.; Georgoulias, V. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am. J. Clin. Oncol. 1998, 21, 226-232.
56. Bradley, G.; Ling, V. P-glycoprotein, multidrug resistance and tumor progression. Canc. Metastasis Rev. 1994, 13, 223-233.
57. Ueda, K.; Cornwell, M.M.; Gottesman, M.M.; Pastan, I.; Roninson, I.B.; Ling, V.; Riordan, J.R. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun. 1986, 141, 956-962.
58. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976, 455, 152-162.
59. Gottesman, M.M.; Pastan, I.; Ambudkar, S-V. P-glycoprotein and multidrug resistance. Curr.Opin. Genet. Dev. 1996, 6, 610-617.
60. Sandor, V.; Fojo, T.; Bates, S.E. Future perspectives for the development of P-glycoprotein modulators. Drug Resist. Updat. 1998, 1, 190-200.
61. Chaudhary, P.M.; Roninson, I.B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Canc. Inst. 1993, 85, 632-639.
62. Sun, J.; He, Z.G.; Cheng, G.; Wang, S.J.; Hao, X.H.; Zou, M.J. Multidrug resistance P-glycoprotein: Crucial significance in drug disposition and interaction. Med. Sci. Mon. 2004, 10, RA5-RA14.
63. Mirski, S.E.; Cole, S.P. Multidrug resistance in small cell lung cancer. In Drug Resistance in Oncology; Bernal, S.D., Ed.; Marcel Dekker Inc.: New York, NY, USA, 1997; pp. 27-77.
64. Rudas, M.; Filipits, M.; Taucher, S.; Stranzl, T.; Steger, G.G.; Jakesz, R.; Pirker, R.; Pohl, G. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Canc. Res. Treat. 2003, 81, 149-157.
65. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Canc. Res. 1993, 53, 4595-4602.
66. Dantzig, A.H.; Shepard, R.L.; Cao, J.; Law, K.L.; Ehlhardt, W.J.; Baughman, T.M.; Bumol, T.F.; Starling, J.J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Canc. Res. 1996, 56, 4171-4179.
67. Morjani, H.; Aouali, N.; Belhoussine, R.; Veldman, R.J.; Levade, T.; Manfait, M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int. J. Canc. 2001, 94, 157-165.
68. Veldman, J.; Klappe, K.; Hinrichs, J.; Hummel, I.; van der Schaaf, G.; Sietsma, H.; Kok, J.; Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J. 2002, 16, 1111-1113.
69. Nicholson, K.; Quinn, D.; Kellett, G.; Warr, J. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br. J. Canc. 1999, 81, 423-430.
70. De Rosa, M.F.; Sillence, D.; Ackerley, C.; Lingwood, C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 2004, 279, 7867-7876.
71. Pastan, I.; Gottesman, M.; Ueda, K.; Lovelace, E.; Rutherford, A.; Willingham, M. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. USA 1988, 85, 4486-4490.
72. Shin, I.S.; Ishii, S.; Shin, J.S.; Sung, K.I.; Park, B.S.; Jang, H.Y; Kim, B.W. Globotriaosylceramide (Gb3) content in HeLa cells is correlated to Shiga toxin-induced cytotoxicity and Gb3 synthase expression. BMB Rep. 2009, 31, 310-314.
73. Arab, S.; Rutka, J.; Lingwood, C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol. Res. 1999, 11, 33-39.
74. Ishitoya, S.; Kurazono, H.; Nishiyama, H.; Nakamura, E.; Kamoto, T.; Habuchi, T.; Terai, A.; Ogawa, O.; Yamamoto, S. Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice. J. Urol. 2004, 171, 1309-1313.
75. Salhia, B.; Rutka, J.T.; Lingwood, C.; Nutikka, A; Van Furth, W.R. The treatment of malignant meningioma with verotoxin. Neoplasia 2002, 4, 304-311.
76. Johannes, L.; Decaudin, D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 2005, 12, 1360-1368.
77. El Alaoui, A.; Schmidt, F.; Amessou, M.; Sarr, M.; Decaudin, D.; Florent, J.C.; Johannes, L. Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug. Angew. Chem. Int. Ed. Engl. 2007, 46, 6469-6472.
78. Vingert, B.; Adotevi, O.; Patin, D.; Jung, S.; Shrikant, P.; Freyburger, L.; Eppolito, C.; Sapoznikov, A.; Amessou, M.; Quintin-Colonna, F.; Fridman, W.H.; Johannes, L., Tartour, E. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur. J. Immunol. 2006, 36, 1124-1135.
79. Bast, D.J.; Sandhu, J.; Hozumi, N.; Barber, B.; Brunton, J. Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30. Infect. Immun. 1997, 65, 2978-2982.
80. Brozovic, A.; Osmak, M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Canc. Lett. 2007, 251, 1-16.